News
Why Nabriva Therapeutics PLC Is Skyrocketing
Investors in Nabriva Therapeutics (NASDAQ: NBRV) are having a wonderful start to the trading week. Shares of the clinical-stage biotech focused on antibiotics rose 36% as of 11:30 a.m. EDT on....
3 High-Yield Healthcare Stocks
One downside to a long-lasting bull market is that the market's dividend yield declines. That's a big problem for retirees who rely on their portfolio to meet their income needs.Even in today's....
3 Value Stocks for Smart Investors
Value investors know that getting a good stock at a good price can be difficult, particularly in markets like we face to day, but it's always worth it when you find one. They tend to offer the....
3 Value Stocks for Smart Investors
Value investors know that getting a good stock at a good price can be difficult, particularly in markets like we face to day, but it's always worth it when you find one. They tend to offer the....
3 Value Stocks for Smart Investors
Value investors know that getting a good stock at a good price can be difficult, particularly in markets like we face to day, but it's always worth it when you find one. They tend to offer the....
3 High-Yield Healthcare Stocks
One downside to a long-lasting bull market is that the market's dividend yield declines. That's a big problem for retirees who rely on their portfolio to meet their income needs.Even in today's....
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
There is perhaps no scarier word in the English language than "cancer." More than 15.5 million Americans who were alive as of Jan. 1, 2016, have had cancer at some point in their lives, according....
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
There is perhaps no scarier word in the English language than "cancer." More than 15.5 million Americans who were alive as of Jan. 1, 2016, have had cancer at some point in their lives, according....
Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You?
Billionaire George Soros is an iconic figure in the world of investing because of his unique ability to consistently beat the broader markets. As such, the quarterly 13F filings of his namesake....
5 Marijuana Stocks Overflowing With Cash
Marijuana may be illegal at the federal level, but that hasn't slowed growth of the drug one iota within the U.S. or North America. In June, Mexico fully legalized medical cannabis, and right now....
3 Stocks to Hold for the Next Century
"Buy and hold" sounds like a simple investing strategy, but it only works if you're confident in your stocks for the very long haul. Titans topple all the time, and truly secular investments are....
3 Stocks to Hold for the Next Century
"Buy and hold" sounds like a simple investing strategy, but it only works if you're confident in your stocks for the very long haul. Titans topple all the time, and truly secular investments are....
Jeff Sessions May Soon Have a Green Light to Wage War on Medical-Marijuana Businesses
The U.S. marijuana industry has witnessed a number of major changes over the past two-plus decades. Since 1996, when California became the first state to legalize medical cannabis for....
Don't Make This Huge Mistake With Celgene
Several years ago, I started to look seriously at investing in Celgene (NASDAQ: CELG) stock. Someone I knew told me that I probably shouldn't get too excited about the biotech. I'm glad I didn't....
Don't Make This Huge Mistake With Celgene
Several years ago, I started to look seriously at investing in Celgene (NASDAQ: CELG) stock. Someone I knew told me that I probably shouldn't get too excited about the biotech. I'm glad I didn't....
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Johnson & Johnson (NYSE: JNJ) reported anemic overall sales growth in the first half of 2017. The big healthcare company even saw a decline in year-over-year earnings during the period.....
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Johnson & Johnson (NYSE: JNJ) reported anemic overall sales growth in the first half of 2017. The big healthcare company even saw a decline in year-over-year earnings during the period.....
Loxo Oncology's Up 230% in the Past Year -- Can You Still Make Money Buying It?
Loxo Oncology (NASDAQ: LOXO) is one of biotech's best-performing stars this past year, and shares could still have room to run higher if the FDA cooperates with an OK for its lead drug,....
Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb
You can call them "frenemies." Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) are friends when it comes to blockbuster blood thinner Eliquis. But the two big pharma companies are enemies....
Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb
You can call them "frenemies." Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) are friends when it comes to blockbuster blood thinner Eliquis. But the two big pharma companies are enemies....
3 Stocks to Buy and Hold for Decades
Trading in and out of stocks may be exciting, but it's no way to build wealth. Buying shares of high-quality companies and holding on for the long haul is a far better alternative.We asked three....
3 Stocks to Buy and Hold for Decades
Trading in and out of stocks may be exciting, but it's no way to build wealth. Buying shares of high-quality companies and holding on for the long haul is a far better alternative.We asked three....
Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?
Many healthcare stocks muddled along over the past week. That wasn't the case, though, for three stocks of companies operating in very different parts of the healthcare spectrum.Shares of Halozyme....
Is ImmunoGen Running Out of Steam, or Taking a Breather?
There's good news and bad news for ImmunoGen (NASDAQ: IMGN) shareholders. The good news is that the biotech stock is up more than 230% so far in 2017. The bad news? Shares have dropped nearly 20%....
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
The global pharmaceutical industry is a giant, in case you didn't already know it. According to a 2016 report from the International Trade Administration (ITA), global sales of pharmaceuticals are....